Headlines Specialties Covid-19 Trending Feeds ASCO20 Videos

Elizabeth Plimack, MD @ERPlimackMD @FoxChaseCancer #ASCO20 Updated analysis of KEYNOTE-426

Oncology Tube - Elizabeth Plimack, MD @FoxChaseCancer gives an updated analysis of KEYNOTE-426 at ASCO 2020 Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC) Bottom line: The randomized, open-label, phase 3 research KEYNOTE-426 (NCT02853331) showed that pembrolizumab (pembro) + axitinib (axi) significantly improved OS, PFS, and ORR vs. sunitinib as...

Read the full article here

Related Content